Breast-conserving surgery and sentinel lymph node biopsy for breast cancer and their correlation with the expression of polyligand proteoglycan-1

Table 1 Comparison of general clinical data between the observation group and the control group, n (%)

Group	Cases	Age (yr)	Course of the disease (mo)	AJCC stage		Site		Tissue types
				I	II	Outer quadrant	Non outer quadrant	Invasive ductal carcinoma	Others
Observation group	44	51.03 ± 12.11	11.06 ± 3.35	26 (59.09)	18 (40.91)	26 (59.09)	18 (40.91)	33 (75.00)	11 (25.00)
Control group	36	49.10 ± 11.45	10.42 ± 4.03	19 (52.78)	17 (47.22)	21 (58.33)	15 (41.67)	24 (66.67)	12 (33.33)
t/χ2		0.727	0.776	0.321		0.878		0.671
P value		0.470	0.440	0.571		0.349		0.413

AJCC: American Joint Committee on Cancer.

Table 2 Comparison of operation related indexes between observation group and control group

Group	Cases	Intraoperative blood loss (mL)	Operation time (min)	Hospital stay (d)
Observation group	44	65.51 ± 9.94	65.59 ± 9.40	14.80 ± 3.03
Control group	36	120.17 ± 13.35	105.51 ± 8.81	24.41 ± 3.80
t		-20.977	-19.435	-12.587
P value		0.000	0.000	0.000

Table 3 Comparison of complications between the observation group and the control group, n (%)

Groups	Cases	Complication
		Hemorrhage	Effusion	Upper extremity edema	Other	Total
Observation group	44	1 (2.27)	2 (4.55)	1 (2.27)	1 (2.27)	5 (11.36)
Control group	36	3 (8.33)	3 (8.33)	6 (16.67)	4 (11.11)	16 (44.44)
χ2						11.192
P value						0.000

Table 4 Comparison of polyligand proteoglycan-1 expression in lesions of observation group and control group, n (%)

Group	Cases	Positive expression rate of SDC-1	χ2	P value
Observation group	44	11 (25.00)	0.084	0.771
Control group	36	8 (22.22)

SDC-1: Polyligand proteoglycan-1 (syndecan-1).

Table 5 Relationship between polyligand proteoglycan-1 expression and clinicopathological characteristics of breast cancer, n (%)

Clinicopathological features	Cases	Positive expression rate of SDC-1	χ2	P value
Age (yr)			0.225	0.635
< 50	30	8 (26.67)
≥ 50	50	11 (22.00)
Course of the disease			0.133	0.716
< 12 mo	35	9 (25.71)
≥ 12 mo	45	2 (5.71)
AJCC stage			5.824	0.016
I	45	17 (37.78)
II	35	5 (14.29)
Site			0.008	0.931
Outer quadrant	47	11 (23.40)
Non outer quadrant	33	8 (24.24)
Tissue type			0.097	0.755
Invasive ductal carcinoma	57	13 (22.81)
Others	23	6 (26.09)
Treatment plan			0.084	0.771
Breast conserving surgery plus sentinel lymph node biopsy	44	11 (25.00)
Total mastectomy	36	8 (22.22)

SDC-1: Polyligand proteoglycan-1 (syndecan-1); AJCC: American Joint Committee on Cancer.